The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis

The future of combined immunotherapy (a PD-1/PD-L1 plus a CTLA-4 antagonist) is very bright. However, besides improving efficacy, combined therapy increases treatment-related adverse events (TRAEs). Also, the ...

Source: BMC Cancer - June 10, 2019 Category: Cancer & Oncology Authors: Lihu Gu, Parikshit Asutosh Khadaroo, Hui Su, Liya Kong, Liangliang Chen, Xianfa Wang, Xinlong Li, Hepan Zhu, Xin Zhong, Junhai Pan and Manman Chen Tags: Research article Source Type: research